Post

New research · Hematology
Current oncology (Toronto, Ont.) · 4d
GuidelineCurrent oncology (Toronto, Ont.) · 2026

Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus.

Andre C Schuh, Nicholas Chornenki, Mohamed A Elemary … Joseph Brandwein
Read paper
HematologyGuideline
“

As more new targeted agents become available and hypomethylating agent-based triplet combinations are used more widely, we fully anticipate that we will, in some years' time, write a fourth guideline on the management of acute myeloid leukemia in older patients.

Management of Acute Myeloid Leukemia in Older Patients: An Updated Canadian Consensus.

Andre C Schuh … Joseph Brandwein
Current oncology (Toronto, Ont.) · 2026
Background

These are the third Canadian consensus guidelines on the management of acute myeloid leukemia (acute myeloid leukemia) in older patients.

More results

The first was published in 2013, and the second in 2017.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0.861
the combined model's improved ability to correctly diagnose liver cancer
Guideline
50 and 70 years of age
Australians within this age range are eligible for lung cancer screening
Review
80%
experts agreed on most questions about managing second breast cancer events
Study
81 cardiac deaths
potential reduction in heart-related deaths for patients switching to zanubrutinib
Cohort Study
79.2%
79.2% of patients on second-line nilotinib achieved major molecular response.
Cohort Study
AUC = 0.86
An AUC of 0.86 indicates good predictive performance for acute respiratory distress syndrome.
Cohort Study
0.24
chemo/RETi had a lower risk of cancer worsening or death
Cohort Study
3.8-fold
Sickle cell disease recipients had 3.8-fold higher odds of DNA Damage Response-mutant clonal hematopoiesis.